Antidepressant market gets boost
The global antidepressant market is the largest and fastest-growing segment of the central nervous system market, according to a new report released by Datamonitor, New York.
The global antidepressant market is the largest and fastest-growing segment of the central nervous system market, according to a new report released by Datamonitor, New York.
Driven by increased use of selective serotonin re-take inhibitors, the antidepressant market grew more than 50% between 1994 and 1996. Datamonitor attributes this upsurge to greater awareness of depression and to the emergence of effective selective serotonin re-uptake inhibitors.
SSRIs have been heavily promoted since Indianapolis-based Eli Lilly launched Prozac in 1985. As a result, physician and patient awareness of depression has improved, and physicians have taken a pharmacological approach to even mild cases of depression.
In terms of volume, antidepressants other than SSRIs remain the predominant choice for treating depression, particularly in Europe. Known as tricyclic antidepressants, the products are cheaper, clinically effective and more extensively studied than selective serotonin re-take inhibitors.
But in terms of value, SSRIs are taking the lion's share: last year, 74% of sales in the $7.1 billion market were cornered by SSRIs. Prozac, the most prescribed SSRI, accounts annually for $2.4 billion in sales.
Higher prices don't seem to be damaging SSRIs' popularity with prescribers. Their improved side-effect profiles and relative safety in cases of overdose seem to outweigh cost considerations, according to the report. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
